Kineta announces TuHURA Biosciences extends exclusivity agreement for KVA12123
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 02 2024
0mins
Should l Buy ?
Agreement Extension: TuHURA Biosciences is extending its exclusivity and right of first offer agreement for Kineta's KVA12123 antibody, allowing for two additional 10-day periods, with Kineta receiving $150,000 for each extension.
Collaboration Update: Kineta and TuHURA are collaborating on the VISTA-101 clinical trial and a Phase 1 program for advanced solid tumor cancer, following a $5M nonrefundable payment made by TuHURA in July.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
